

PC-529-T025

## Monoclonal Antibody to CD11c PerCP (25 tests)

<b>Clone:</b>	BU15
<b>Isotype:</b>	Mouse IgG1
<b>Specificity:</b>	The antibody BU15 reacts with CD11c (alphaX, p150), a 150 kDa integrin expressed mainly on dendritic cells and tissue macrophages. HLDA III; WS Code M 256 HLDA V; WS Code AS S143 HLDA VI; WS Code AS Ref.6
<b>Immunogen:</b>	Dendritic cells of synovial fluid
<b>Species Reactivity:</b>	Human, Canine (Dog), Monkey, Other not determined
<b>Preparation:</b>	The purified antibody is conjugated with Peridinin-chlorophyll-protein complex (PerCP) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
<b>Storage Buffer:</b>	The reagent is provided in phosphate buffered saline (PBS) containing 15 mM sodium azide and 0.2% (w/v) high-grade protease free Bovine Serum Albumin (BSA) as a stabilizing agent.
<b>Storage / Stability:</b>	Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label. Short-term exposure to room temperature should not affect the quality of the reagent. However, if reagent is stored under any conditions other than those specified, the conditions must be verified by the user.
<b>Usage:</b>	The reagent is designed for Flow Cytometry analysis of human blood cells using 10 µl reagent / 100 µl of whole blood or 10 <sup>6</sup> cells in a suspension. The content of a vial (0.1 ml) is sufficient for 25 tests.
<b>Expiration:</b>	See vial label
<b>Lot Number:</b>	See vial label
<b>Background:</b>	CD11c (p150, alphaX integrin subunit) forms complex with CD18 (beta2 integrin subunit) and is expressed mainly on tissue macrophages and dendritic cells. CD11c binds to complement fragment iC3b, fibrinogen, VCAM-1 and ICAM-2 or e.g. CD90. Like other beta2 integrins, CD11c/CD18 plays roles in cell migration and phagocytosis. Moreover, interaction of CD11c/CD18 with plasminogen regulates plasmin activities, and interaction with heparin counteracts binding of iC3b.

**For laboratory research only, not for drug, diagnostic or other use.**

**Antibodies****References:**

- \*Sadhu C, Ting HJ, Lipsky B, Hensley K, Garcia-Martinez LF, Simon SI, Staunton DE: CD11c/CD18: novel ligands and a role in delayed-type hypersensitivity. *J Leukoc Biol.* 2007 Jun;81(6):1395-403.
- \*Bullard DC, Hu X, Adams JE, Schoeb TR, Barnum SR: p150/95 (CD11c/CD18) expression is required for the development of experimental autoimmune encephalomyelitis. *Am J Pathol.* 2007 Jun;170(6):2001-8.
- \*Vorup-Jensen T, Chi L, Gjelstrup LC, Jensen UB, Jewett CA, Xie C, Shimaoka M, Linhardt RJ, Springer TA: Binding between the integrin alphaXbeta2 (CD11c/CD18) and heparin. *J Biol Chem.* 2007 Oct 19;282(42):30869-77.
- \*Gang J, Choi J, Lee JH, Nham SU: Identification of critical residues for plasminogen binding by the alphaXI-domain of the beta2 integrin, alphaXbeta2. *Mol Cells.* 2007 Oct 31;24(2):240-6.
- \*Hogg N, Takacs L, Palmer DG, Selvendran Y, Allen C: The p150,95 molecule is a marker of human mononuclear phagocytes: comparison with expression of class II molecules. *Eur J Immunol.* 1986 Mar;16(3):240-8.
- \*Leukocyte Typing III., McMichael A. J. et al (Eds.), Oxford University Press (1987).
- \*Trowald-Wigh G, Johannisson A, Hansson L: Canine neutrophil adhesion proteins and Fc-receptors in healthy dogs and dogs with adhesion protein deficiency, as studied by flow cytometry. *Vet Immunol Immunopathol.* 1993 Oct;38(3-4):297-310.
- \*Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).
- \*Van der Vieren M, Le Trong H, Wood CL, Moore PF, St John T, Staunton DE, Gallatin WM: A novel leukointegrin, alpha d beta 2, binds preferentially to ICAM-3. *Immunity.* 1995 Dec;3(6):683-90.
- \*Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997).
- \*Rezzonico R, Imbert V, Chicheportiche R, Dayer JM: Ligation of CD11b and CD11c beta(2) integrins by antibodies or soluble CD23 induces macrophage inflammatory protein 1alpha (MIP-1alpha) and MIP-1beta production in primary human monocytes through a pathway dependent on nuclear factor-kappaB. *Blood.* 2001 May 15;97(10):2932-40.
- \*Myou S, Zhu X, Boetticher E, Qin Y, Myo S, Meliton A, Lambertino A, Munoz NM, Hamann KJ, Leff AR: Regulation of adhesion of AML14.3D10 cells by surface clustering of beta2-integrin caused by ERK-independent activation of cPLA2. *Immunology.* 2002 Sep;107(1):77-85.
- \*Sadhu C, Hendrickson L, Dick KO, Potter TG, Staunton DE: Novel Tools for Functional Analysis of CD11c: Activation-Specific, Activation-Independent, and Activating Antibodies. *J Immunoassay Immunochem.* 2008;29(1):42-57.
- \*Angel CE, Lala A, Chen CJ, Edgar SG, Ostrovsky LL, Dunbar PR: CD14+ antigen-presenting cells in human dermis are less mature than their CD1a+ counterparts. *Int Immunol.* 2007 Nov;19(11):1271-9.
- \*And many other.

**For laboratory research only, not for drug, diagnostic or other use.**